喘中特泽佩卢马布和杜皮卢马布的比较有效性:一项跨国回顾性队列研究
Chun-Tse Hung1, Yu-Chien Hung2, Chen-Yen An3
1Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, Mich.
The journal of allergy and clinical immunology. In practice
|November 29, 2025
概括
这项研究发现,dupilumab和tezepelumab之间的喘恶化风险没有显著差异. 这两种生物药物在减少严重喘患者的恶化和系统性皮质类固醇使用方面表现出类似的有效性.
科学领域:
- 肺部病理学 肺部病理学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 严重的喘治疗通常涉及生物药物.
- 杜皮卢马布和特泽佩卢马布是治疗严重喘的批准选择.
- 有限的现实世界数据存在,比较它们的有效性.
研究的目的:
- 为了比较tezepelumab与dupilumab的实际有效性.
- 评估它们对减少喘恶化的影响.
- 评估系统性皮质类固醇使用作为次要结局.
主要方法:
- 使用TrinetX数据库进行回顾性队列研究.
- 包括开始使用dupilumab或tezepelumab的成年人 (2021-2024).
- 倾向性得分匹配用于比较1年的结果.
主要成果:
- 在dupilumab和tezepelumab之间喘恶化风险没有显著差异 (HR 0.96).
- 在各个子组中观察到类似的有效性 (乙氨基基,COPD,先前的生物药物,肥胖症).
- 系统性皮质类固醇使用也显示两种生物药物之间没有显著差异 (HR 0.97).
结论:
- 杜皮卢马布和特泽佩卢马布在减少喘恶化方面表现出相似的有效性.
- 需要进一步的研究来解决潜在的残留混问题.
- 在临床实践中选择生物疗法的指导要求进行更多的研究.
相关概念视频
Antiasthma Drugs: Leukotriene Modifiers
1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.7K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K
Asthma-III: Symptoms and Complications
3.2K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma
3.2K
Antiasthma Drugs: Methylxanthines
1.5K
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
1.5K
Asthma-IV: Diagnostic and Management
3.0K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.0K


